In the present study, we first analyzed the expression levels of PDE2A in pan-cancer and showed that it was significantly downregulated in the vast majority of tumor tissues compared to non-tumor tissues, including HCC, except for two immune system tumors, DLBC and THYM. This evidence concerns the gene PDE2A and hepatocellular carcinoma.